Estrogen therapy in postmenopausal osteoporosis what we know and what we don't

被引:0
|
作者
Roux, C [1 ]
机构
[1] COCHIN TEACHING HOSP,BONE DIS RES CTR,PARIS,FRANCE
来源
REVUE DU RHUMATISME | 1997年 / 64卷 / 06期
关键词
estrogen; osteoporosis; menopause; densitometry;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Replacement estrogen therapy is of proven efficacy for the prevention and treatment of postmenopausal bone loss, Oral and transdermal 17 beta estradiol have provided similar benefits in clinical studies, The lowest effective doses are 0.625 mg per day for conjugated estrogens, 2 mg per day for oral 17 beta estradiol 1.5 mu g per day for 17 beta estradiol gel, and 50-mu g 17 beta estradiol patch per day. Bone mineral density should be monitored if lower doses are used, Several epidemiologic studies found that a decrease in the incidence of osteoporotic fractures was achieved only when the duration of estrogen replacement therapy exceeded seven years, It follows that replacement therapy should be started at cessation of menses, if possible, However delayed replacement therapy (i.e., at 65 years of age) is unquestionably effective.
引用
收藏
页码:402 / 409
页数:8
相关论文
共 50 条
  • [21] What do we know about the effects of spaceflight on bone?
    Turner, RT
    JOURNAL OF APPLIED PHYSIOLOGY, 2000, 89 (02) : 840 - 847
  • [22] Osteoporosis: what the clinician needs to know?
    Balzano, Rosario Francesco
    Mattera, Maria
    Cheng, Xiaoguang
    Cornacchia, Samantha
    Guglielmi, Giuseppe
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2018, 8 (01) : 39 - 46
  • [23] ESTROGEN PROGESTAGEN AS STANDARD THERAPY OF POSTMENOPAUSAL OSTEOPOROSIS
    DOREN, M
    SCHNEIDER, HPG
    HESCH, RD
    MEDIZINISCHE WELT, 1993, 44 (02): : 99 - 101
  • [24] What Can We Learn from Bone Biology for the Treatment for Osteoporosis?
    G. R. Mundy
    Osteoporosis International, 1999, 9 (Suppl 2) : S40 - S47
  • [25] Epidemiology of osteoporotic fractures in Brazil: what we have and what we need
    Pinheiro, Marcelo de Medeiros
    Eis, Sergio Ragi
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2010, 54 (02) : 164 - 170
  • [26] Bisphosphonate-induced femoral fragility fractures: What do we know?
    Sayed-Noor, Arkan S.
    Kadum, Bakir K.
    Sjoden, Goran O.
    ORTHOPEDIC RESEARCH AND REVIEWS, 2010, 2 : 27 - 34
  • [27] Sleep disruptions and bone health: what do we know so far?
    Swanson, Christine M.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2021, 28 (04) : 348 - 353
  • [28] What do we know about atypical femoral fractures? Insights and enigmas
    Audran, Maurice
    Cortet, Bernard
    Thomas, Thierry
    JOINT BONE SPINE, 2011, 78 (06) : 568 - 571
  • [29] Focus on Sex and Gender: What We Need to Know in the Management of Rheumatoid Arthritis
    Maranini, Beatrice
    Bortoluzzi, Alessandra
    Silvagni, Ettore
    Govoni, Marcello
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (03):
  • [30] What do we think about selective estrogen receptor modulators (SERMS)?
    Cortet, B
    REVUE DE MEDECINE INTERNE, 2001, 22 (12): : 1173 - 1176